Firma Nomad Bioscience, Autor bei Presse-Blog

Nomad Bioscience receives grants from Investment Bank Saxony-Anhalt for research on use of griffithsin and other plant lectins for prevention and therapy of SARS-CoV-2 infections

1. Juli 20212. Juli 2021 Firma Nomad BioscienceBiotechnik??future, cells, influenza, may, measures, mutation, nasal, nomad, nomads, platform, respiratory, sachsen, sugar, treatment, vaccines

Nomad Bioscience GmbH was awarded two significant grants from Investment Bank Saxony-Anhalt (Investitionsbank Sachsen-Anhalt) for development of griffithsin and other plant-derived lectins as preventative therapies against coronaviruses. Lectins are sugar-binding proteins some of which effectively prevent attachment of enveloped viruses Mehr

NOMAD Bioscience Published Milestone Paper in Nature Plants Describing its RNA-Based Rapid Transient Reprogramming of Crop Plants for Agronomic Performance

16. Februar 202116. Februar 2021 Firma Nomad BioscienceBiotechnikbenthamiana, dna, gene, genome, nicotiana, nomad, nomads, orphan, paper, production, research, rna, swift, vaccines, with

NOMAD Bioscience announces the publication in Nature Plants (Torti et al. (2021) Nature Plants 7; https://www.nature.com/articles/s41477-021-00851-y) a research paper describing NOMAD’s novel transient RNA replicon-based process of controlling agronomic performance of crop plants. The process does not involve genetic modification Mehr

NOMAD Bioscience Receives Its GRAS Regulatory Clearance In USA For Plant-Made Natural Thaumatin II As Flavour Modifier

15. Dezember 2020 Firma Nomad BioscienceBiotechnikalcoholic, caloric, fruit, market, milk, nectars, new, nomad, nomads, production, sugar, sweeteners, thaumatin, thaumatins, with

NOMAD Bioscience GmbH received a formal ‘no questions’ letter from the US Food and Drug Administration (FDA) in response to NOMAD’s GRAS notice GRN 920 describing use of plant-produced Thaumatin II as flavour modifier. Thaumatin II is natural non-caloric high Mehr

NOMAD BIOSCIENCE Enters Into Agreement with CTAEX, Spain, To Conduct Its First Field Trials With Plants Producing Non-Caloric Sweetener Thaumatin II in Extremadura, Spain

10. November 2020 Firma Nomad BioscienceBiotechnikalign, caloric, cell, Exploration, extremadura, market, new, nomad, nomads, origin, production, research, smart, thaumatin, with

NOMAD BIOSCIENCE GmbH, Munich, Germany (“NOMAD”) is pleased to announce that it has entered into a research and development agreement with CENTRO TECNOLOGICO NACIONAL AGROALIMENTARIO EXTREMADURA (“CTAEX”), Badajoz, Spain. In accordance with the Agreement, CTAEX is expected to conduct in Mehr

NOMADS UAB, Lithuania, Receives a Research Grant from Lithuanian Business Support Agency LVPA

14. Oktober 202014. Oktober 2020 Firma Nomad BioscienceBiotechnikantibiotic, bacteriocins, Biotech, company, devices, Exploration, market, medical, new, nomad, nomads, pseudomonas, research, secure, with

NOMADS UAB, Vilnius, Lithuania (“NOMADS”), a wholly owned subsidiary of Nomad Bioscience GmbH, Munich, Germany, is pleased to announce that the Company has been awarded a research grant from LVPA (Lietuvos Verslo Paramos Agentūra, Lithuanian Business Support Agency) to extend Mehr

NOMAD Bioscience Receives Its GRAS Regulatory Clearance In USA For Plant-Made Natural Thaumatin II As Sweetener

30. September 2020 Firma Nomad BioscienceBiotechnikbeet, caloric, content, ingredients, market, new, nomad, petition, production, sugar, sweeteners, thaumatin, thaumatins, thousand, with

NOMAD Bioscience received a formal ‘no questions’ letter from the US Food and Drug Administration (FDA) in response to NOMAD’s GRAS notice GRN 910 describing use of plant-produced Thaumatin II as sweetener. Thaumatin II is natural noncaloric high intensity sweetener Mehr

Nomad Bioscience and Fraunhofer Institute for Cell Therapy and Immunology Enter into a Research and Development Agreement

15. September 2020 Firma Nomad BioscienceBiotechnikbacteriocins, Biotech, cell, drugs, fraunhofer, influenza, market, medical, new, nomad, pseudomonas, research, strong, therapy, with

Nomad Bioscience GmbH (“NOMAD”) is pleased to announce that the Company has entered into a broad research and development agreement with the Department of Drug Design and Target Validation of the Fraunhofer Institute for Cell Therapy and Immunology (Fraunhofer IZI), headquartered in Mehr

Autor: Firma Nomad Bioscience